Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice

B-cell activating factor (BAFF) is regarded as a new therapeutic target in autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Along with other researchers, we have demonstrated that BAFF inhibitor atacicept (TACI-IgG) suppresses lupus and experimental allergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoqian, Xiao, He, Wei, Yinxiang, Liu, Xiaoling, Han, Gencheng, Chen, Guojiang, Hou, Chunmei, Shen, Beifen, Li, Yan, Wang, Renxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Society of Experimental and Clinical Immunology 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637387/
https://www.ncbi.nlm.nih.gov/pubmed/26557026
http://dx.doi.org/10.5114/ceji.2015.52826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637387/
https://www.ncbi.nlm.nih.gov/pubmed/26557026
http://dx.doi.org/10.5114/ceji.2015.52826

Ejemplares similares